Abstract: Methods for the synthesis of arginine-containing peptides are provided. The methods include a deprotection step that minimizes the transfer of by-products deriving from cleaved sulfonyl-5 based side chain protecting groups from arginine to amino acids carrying electron rich side chains.

Abstract: The present invention relates to novel selective melanocortin-1 receptor (MC1R) agonists as well as the use thereof as skin tanning agents.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to novel selective melanocortin-1 receptor (MC1R) agonists as well as the use thereof as skin tanning agents.

Abstract: Methods for the synthesis of arginine-containing peptides are provided. The methods include a deprotection step that minimizes the transfer of by-products deriving from cleaved sulfonyl-5 based side chain protecting groups from arginine to amino acids carrying electron rich side chains.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for lightening natural skin color.

Abstract: The present invention relates to novel tetrapeptides as well as the use thereof as antimicrobial agents.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for lightening natural skin color.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

Abstract: Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R1 is H, C1-C20-alkyl, cycloalkyl or aryl-C1-C4-alkyl, n is 1-4, X is —O—, —NH— or —NR2— and R2H or C1-C20-alkyl; and at least one compound corresponding to the above formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid; use of these compounds and of the composition for stimulating the synthesis of the proteins of the basement membrane; and also both those compounds of the formula (I) in which X is —NR2— and both R1 and R2 are different from H, and the compounds corresponding to formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid, as such.